Adding radiotherapy to checkpoint inhibitors in lung cancer

Immune-related adverse events are not more likely to occur when patients with metastatic lung cancer receive a combination of immunotherapy with checkpoint inhibitors and thoracic radiotherapy compared with those who receive checkpoint inhibitor therapy alone, a retrospective cohort study suggests.

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>